Selective subtype alpha 2 adrenergic agents and methods for use thereof

Details for Australian Patent Application No. 2009228449 (hide)

Owner Allergan, Inc.

Inventors Gil, Daniel W.; Li, Ling; Heidelbaugh, Todd M.; Takeuchi, Janet A.; Chow, Ken; Kedzie, Karen M.; Fang, Wenkui K.

Agent Davies Collison Cave

Pub. Number AU-A-2009228449

PCT Pub. Number WO2009/120648

Priority 12/408,823 23.03.09 US; 61/038,928 24.03.08 US

Filing date 24 March 2009

Wipo publication date 1 October 2009

International Classifications

A61K 31/4166 (2006.01)

A61K 31/00 (2006.01)

A61K 31/421 (2006.01) - 1,3-Oxazoles, e.g. pemoline, trimethadione

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61P 25/02 (2006.01) Drugs for disorders of the nervous system

A61P 25/04 (2006.01) Drugs for disorders of the nervous system

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

21 October 2010 PCT application entered the National Phase

  PCT publication WO2009/120648 Priority application(s): WO2009/120648

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009228450-UPS frequency converter and line conditioner

2009228423-Method for controlling the formation of smoke constituents in an electrical aerosol generating system